1. Scrip
  2. >>Business

Calithera Biosciences: UCSF Spin-out Takes $40 Million First Round

 
• By Paul Bonanos

An investor syndicate led by Morgenthaler Ventures has backed cancer drug researcher Calithera Biosciences Inc. with $40 million in Series A funding, intended to support development of small-molecule compounds that activate caspases.

An investor syndicate led by Morgenthaler Ventures has backed cancer drug researcher Calithera Biosciences Inc. with $40 million in Series A funding, intended to support development of small-molecule compounds that activate caspases. [See Deal] Morgenthaler led the round alongside US Venture Partners, Advanced Technology Ventures, Delphi Ventures, and Mission Bay Capital. The last is closely affiliated with California Institute for Quantitative Biosciences (QB3), the agency that specializes in commercializing technologies developed at three University of California schools in the Bay Area.

Calithera's key innovation was licensed from co-founder James Wells, PhD, a professor in the University of California, San Francisco's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.